<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731521</url>
  </required_header>
  <id_info>
    <org_study_id>STU 122013-077</org_study_id>
    <nct_id>NCT02731521</nct_id>
  </id_info>
  <brief_title>Clinical Development of MR Spectroscopy and Imaging in Brain Cancers</brief_title>
  <official_title>Clinical Development of MR Spectroscopy and Imaging in Brain Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Prevention Research Institute of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Investigators will examine the disease specificity of 2-hydroxyglutarate in non-glioma&#xD;
      brain lesions, and the clinical utility of 2-hydroxyglutarate, glycine and citrate in&#xD;
      isocitrate dehydrogenase (IDH) mutated gliomas and IDH wild type gliomas.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2-hydroxyglutarate (2HG) imaging will identify glioma, tumor progression and response to&#xD;
      therapy noninvasively at an earlier time point than currently detectable with standard MR&#xD;
      imaging. This utility of 2HG can be used for improving the patient care in a more effective&#xD;
      manner when the 2HG imaging is incorporated in regular clinical MR scans in brain tumor&#xD;
      patients. We aim to translate the 2HG MRS protocol into two clinical MR centers at&#xD;
      UTSouthwestern Medical Center: The Mary Nell and Ralph B. Rogers Magnetic Resonance Center&#xD;
      with Philips 1.5Tesla and 3Tesla scanners and The Algur H. Meadows Diagnostic Imaging Center&#xD;
      with a GE 3Tesla scanner. In addition, we will perform Magnetic Resonance (MR) scans in&#xD;
      patients with neurological diseases that can mimic gliomas, including stroke, epilepsy,&#xD;
      encephalitis, and brain metastases in order to establish the specificity of 2HG to malignant&#xD;
      gliomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of 2-hydroxyglutarate (2HG) bio-marker in 170 patients with clinically-proven brain metastasis, multiple sclerosis, epilepsy, stroke, or encephalitis using magnetic resonance spectroscopy (MRS).</measure>
    <time_frame>1-4 scans, average over 36 months</time_frame>
    <description>Measuring amount of 2-hydroxygluterate (2HG) biomarker with MRS.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Malignant Gliomas</condition>
  <condition>Astrocytomas</condition>
  <condition>Oligodendrogliomas</condition>
  <arm_group>
    <arm_group_label>3 Tesla Scanning and 7 Tesla Scanning</arm_group_label>
    <description>Scanning at 3 Tesla and 7 Tesla: Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS) of glioma and non-glioma patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>3 Tesla Scanning</intervention_name>
    <description>Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.</description>
    <arm_group_label>3 Tesla Scanning and 7 Tesla Scanning</arm_group_label>
    <other_name>3T MRI/MRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>7 Tesla Scanning</intervention_name>
    <description>Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.</description>
    <arm_group_label>3 Tesla Scanning and 7 Tesla Scanning</arm_group_label>
    <other_name>7T MRI/MRS</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Glioma patients recruited from UTSW neurosurgery and neuro-oncology clinics.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        (120 Brain Tumor Patients)&#xD;
&#xD;
          -  All races and ethnicities&#xD;
&#xD;
          -  Must meet at least one of the 3 following criteria regarding diagnosis:&#xD;
&#xD;
               -  Histological diagnosis of a brain tumor&#xD;
&#xD;
               -  Pre-operative MR imaging suggestive of a brain tumor&#xD;
&#xD;
               -  Radiographic diagnosis of brain tumor in an inoperable location (e.g. brainstem)&#xD;
&#xD;
          -  Pretreatment evaluations required for eligibility include a medical history, physical&#xD;
             examination, and neurological exam within 30 days prior to study entry.&#xD;
&#xD;
          -  Patient must be able to provide study-specific consent prior to study entry and Health&#xD;
             Insurance Portability and Accountability Act of 1996 (HIPAA) authorization.&#xD;
&#xD;
          -  Karnofsky performance status &gt;70%&#xD;
&#xD;
          -  Life expectancy greater than 3 months.&#xD;
&#xD;
             (50 Non-Tumor Neurological Disorders)&#xD;
&#xD;
          -  All races and ethnicities&#xD;
&#xD;
          -  Patients with clinically-proven multiple sclerosis, temporal lobe epilepsy, stroke, or&#xD;
             encephalitis.&#xD;
&#xD;
             (5 Health Volunteers)&#xD;
&#xD;
          -  18-40 years of age&#xD;
&#xD;
          -  All races and ethnicities&#xD;
&#xD;
          -  Excellent general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under age 18&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Intracranial clips, metal implants, or external clips within 50 cm from the head&#xD;
&#xD;
          -  Metal in eye&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Obesity or any other factors that provide difficulty with supine pose in the magnet&#xD;
&#xD;
          -  Patients who are unable to provide informed consent&#xD;
&#xD;
          -  Patients who are pregnant or nursing&#xD;
&#xD;
          -  Patients with severe kidney dysfunction or uncontrolled cardiac dysfunction&#xD;
&#xD;
          -  Patients who are claustrophobic or have other contraindication to MRI, such as&#xD;
             implanted pacemaker device, vascular clips, surgical clips, prosthetic valves,&#xD;
             paceÂ¬makers, otologic implants&#xD;
&#xD;
          -  Patients with uncontrolled psychiatric manifestations of their brain tumor&#xD;
&#xD;
          -  Patients for 7 Tesla scans can have no metal in the body&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Changho Choi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeannie Baxter, RN</last_name>
    <phone>214-645-2726</phone>
    <email>jeannie.baxter@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucy H Christie, RN</last_name>
    <phone>214-645-2215</phone>
    <email>lucy.christie@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannie Baxter, RN</last_name>
      <phone>214-645-2726</phone>
      <email>jeannie.baxter@utsouthwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lucy H Christie, RN</last_name>
      <phone>214-645-2215</phone>
      <email>lucy.christie@utsouthwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Changho Choi, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Changho Choi</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>MRS Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
    <mesh_term>Oligodendroglioma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

